Standardization of Diagnostic Biomarker Concentrations in Urine: The Hematuria Caveat

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Reid, Cherith N ^a   Stevenson, Michael ^b   Abogunrin, Funso ^b   Ruddock, Mark W ^a   Emmert Streib, Frank ^b   Lamont, John V ^a   Williamson, Kate E ^b  

^a Randox Laboratories Ltd   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; INTERLEUKIN 6; INTERLEUKIN 8; VASCULOTROPIN;

AGED; ARTICLE; BLADDER CANCER; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PATIENT IDENTIFICATION; PROTEIN URINE LEVEL; STANDARDIZATION; URINALYSIS; URINE OSMOLALITY; URINE VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CREATININE; HEMATURIA; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871752522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053354     Document Type: Article

References (33)

1. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M, (2006) The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 7(9): R80.
2. Pisitkun T, Johnstone R, Knepper MA, (2006) Discovery of urinary biomarkers. Mol Cell Proteomics 5: 1760-1771.
3. Hu S, Loo JA, Wong DT, (2006) Human body fluid proteome analysis. Proteomics 6: 6326-6353.
4. Nagaraj N, D'Souza RC, Cox J, Olsen JV, Mann M, (2010) Feasibility of large-scale phosphoproteomics with higher energy collisional dissociation fragmentation. J Proteome Res 9: 6786-6794.
5. Chen YT, Chen CL, Chen HW, Chung T, Wu CC, et al. (2010) Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res 9: 5803-5815.
6. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, et al. (2004) Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004 95: 955-961.
7. Julian BA, Suzuki H, Suzuki Y, Tomino Y, Spasovski G, et al. (2009) Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease. Proteomics Clin Appl 2009 3: 1029-1043.
8. Margel D, Pesvner-Fischer M, Baniel J, Yossepowitch O, Cohen IR, (2011) Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol 59: 113-119.
9. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, et al. (2006) Soluble Fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106: 1701-1707.
10. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, et al. (2012) CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 7: e37797.
11. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, Garcia J, et al. (2000) Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer. Urology 55: 526-532.
12. Miller RC, Brindle E, Holman DJ, Shofer J, Klein NA, et al. (2004) Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations. Clin Chem 50: 924-932.
13. Garde AH, Hansen AM, Kristiansen J, Knudsen LE, (2004) Comparison of uncertainties related to standardization of urine samples with volume and creatinine concentration. Ann Occup Hyg 48: 171-179.
14. Pesic I, Stefanovic V, Muller GA, Muller CA, Cukuranovic R, et al. (2011) Identification and validation of six proteins as marker for endemic nephropathy. J Proteomics 74: 1994-2007.
15. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, et al. (2000) Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163: 348-356.
16. Smalley DM, Sheman NE, Nelson K, Theodorescu D, (2008) Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 7: 2088-2096.
17. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, et al. (2005) Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005 113: 192-200.
18. Goldstein SL, (2011) Acute kidney injury biomarkers: renal angina and the need for a renal troponin I. BMC Med. 9: 135.
19. Seegmiller JC, Sviridov D, Larson TS, Borland TM, Hortin GL, et al. (2009) Comparison of urinary albumin quantification by immunoturbidimetry, competitive immunoassay, and protein-cleavage liquid chromatography-tandem mass spectrometry. Clin Chem 55: 1991-1994.
20. Barratt J, Topham P, (2007) Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 177: 361-368.
21. Lee JW, (2009) Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. Bioanalysis 1: 1461-1474.
22. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) Standards for Reporting of Diagnostic Accuracy: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49: 1-6.
23. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) Standards for Reporting of Diagnostic Accuracy: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49: 7-18.
24. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, et al. (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24): 5746-5756.
25. Sheryka E, Wheeler MA, Hausladen DA, Weiss RM, (2003) Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 62: 162-166.
26. Eissa S, Salem AM, Zohny SF, Hegazy MG, (2007) The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark 3: 275-285.
27. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, et al. (2011) The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 18: 2641-2650.
28. Henry RJ (1974) Clinical Chemistry, Principles and Techniques. New York: Harper and Row. 525p.
29. Bazari H (2007). Approach to the patient with renal disease. In: Goldman L, Ausiello D, editors. Cecil Medicine. Philadelphia: Saunders Elsevier. chap 115.
30. Sertic J, Slavicek J, Bozina N, Malenica B, Kes P, et al. (2007) Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 45: 1347-1352.
31. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O, (2005) Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 51: 1165-1176.
32. Kashif W, Siddiqi N, Dincer AP, Dincer HE, Hirsch S (2003) Proteinuria: how to evaluate an important finding. Cleve Clin J Med 70: 535-7, 541-4, 546-7.
33. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, et al. (2008) The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 5: e207.